Core Laboratories Inc.
CLB
$12.62
$0.302.44%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -14.38% | -36.46% | -39.97% | 58.23% | 88.53% |
| Total Depreciation and Amortization | -5.26% | -5.13% | -4.99% | -6.40% | -8.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 95.64% | 347.04% | 787.86% | -104.32% | -91.75% |
| Change in Net Operating Assets | 127.38% | 118.03% | 80.01% | 48.47% | -15.00% |
| Cash from Operations | 127.47% | 197.25% | 70.07% | 102.99% | -0.67% |
| Capital Expenditure | -23.15% | -15.40% | -33.06% | -12.80% | -3.55% |
| Sale of Property, Plant, and Equipment | 257.94% | -46.95% | -52.42% | -47.14% | -74.33% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 42.30% | 5.59% | -37.77% | 147.70% | -18.65% |
| Cash from Investing | 3.88% | -67.76% | -252.96% | 0.81% | -72.51% |
| Total Debt Issued | -78.22% | -80.92% | -42.93% | 53.60% | 74.14% |
| Total Debt Repaid | 61.14% | 66.54% | 26.37% | -59.40% | -61.07% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -140.96% | -8.76% | -13.99% | -13.16% | 43.58% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -0.43% | -0.48% | -0.59% | -0.75% | -0.81% |
| Other Financing Activities | 85.58% | 57.05% | 42.44% | -9.47% | -105.23% |
| Cash from Financing | -149.16% | -259.38% | -244.40% | -79.50% | 21.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,410.71% | 68.45% | -184.62% | 76.15% | 86.46% |